Send to

Choose Destination
Am J Gastroenterol. 1995 Nov;90(11):1978-80.

Hepatotoxicity from isoniazid and rifampin in inner-city AIDS patients.

Author information

Department of Medicine, Harlem Hospital Center, Columbia University, College of Physicians and Surgeons, New York, New York, USA.



To determine the incidence of hepatotoxicity due to isoniazid and rifampin in inner-city patients with active tuberculosis.


A hospital-based review of 70 consecutive in-patients in a 770-bed, inner-city hospital. The patient population is primarily African-American and Hispanic.


Fifty-eight men and 12 women were followed from 2-12 wk (median 4 wk). Patients had to be treated for at least 2 wk to be eligible for the study. Patients were excluded if they had been on any anti-tuberculous or any other hepatotoxic drug during the 2-month period before their hospitalization. Aminotransferases, alkaline phosphatase, bilirubin, and albumin were obtained at least every 2 wk.


Hepatocellular toxicity, defined as AST and/or ALT greater than 200 IU/L, occurred in eight out of 70 (11.4%) patients. The mean age of these patients was 38.9 yr (22-58 yr). Patients with AIDS were significantly more likely to develop hepatotoxicity than those with any other risk factor (p < 0.01).


Baseline aminotransferases followed by monitoring may be necessary in AIDS patients.

Comment in

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center